Engineered IL13 Variants Direct Specificity of IL13Rα2-Targeted CAR T Cell Therapy

Researchers demonstrated the utility of structure-guided engineering of ligand-based binding domains with appropriate selectivity while validating IL13-mutein CARs with improved selectivity for application to systemic IL13Rα2-expressing malignancies.